Submitted by Viatris
In 2022, Viatris worked with our longtime partner, Direct Relief, to provide essential medicines to people impacted by the ongoing crisis in Ukraine.
“You stepped up in a major way – extraordinarily so. And I cannot thank you enough,” says Direct Relief President and CEO, Thomas Tighe, of the partnership with Viatris.
Learn more about how this partnership made an impact during a time of critical need: https://newsroom.viatris.com/direct-relief-ukraine
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris’ portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, and a variety of over-the-counter consumer products. With more than 38,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn, Instagram and YouTube.
More from Viatris